Mednet Logo

Would you give a PARP inhibitor, and at what dose, to a patient with end-stage renal disease on hemodialysis after completion of 6 cycles of carboplatin and paclitaxel for advanced ovarian cancer?

Community PollStarted

Do you use PARP inhibitors in AOC patients with ESRD on HD after completion of adjuvant carbo/taxol?

25 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet Member
Mednet MemberInvited Expert
Gynecologic Oncology · Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Answered on

This is an interesting question, for which I don't have a quick answer.

When it comes to PARP inhibitors (PARPi), there is compelling data for its use as maintenance therapy as well as recurrent treatment. The article by Kurnit et al., is a nice summary of the data available supporting PARPi use (Kur...

Join for free or sign in to see the full answer